SGLT2 inhibitors × cardiovascular events

TrialThe New England journal of medicine2017

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Bruce Neal et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 10,142 people · 2017

Randomised comparison

Increased cardiovascular events

1.4× to 2.8×

Bigger than 9 in 10 for cardiovascular events

As reported

HR 1.97, 95% CI 1.41–2.75

Not counted

Lowered kidney outcomes

−27%−33% to −21%

Bigger than 6 in 10 on the map

As reported

HR 0.73, 95% CI 0.67–0.79

Not counted

Reduced cardiovascular events

−40%−53% to −23%

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.60, 95% CI 0.47–0.77

Three numbers in the abstract

the abstract, start to end

of albuminuria (hazard ratio, 0.73; 95% CI, 0.67 to 0.79) and the composite outcome of a sustained 40% reduction in the estimated glomerular filtration rate, the need for renal-replacement therapy, or death from renal causes (hazard ratio, 0.60; 95% CI, 0.47 to 0.77).

per 1000 patient-years; hazard ratio, 1.97; 95% CI, 1.41 to 2.75);

← favours treatmentfavours comparator →
could be chance
Kidney outcomes
HR 0.730.67–0.79
Cardiovascular events
HR 0.600.47–0.77
Cardiovascular events
HR 1.971.41–2.75
SGLT2 inhibitorsCardiovascular eventsKidney outcomes
1 / 4

3,183 papers cite itlatest 60 shown

2017
2026
this paperpooled ittrialcites it

13 trials

Full record →Abstract, authors, funding and every citing paper · PMID 28605608